Table 2.
Quarter 1 | Quarter21 | Quarter 3 | Quarter 4 | Overall | |||||
---|---|---|---|---|---|---|---|---|---|
| |||||||||
BP Metric | Mean (SD) | Δ Estimate (95% CI) |
Mean (SD) | Δ Estimate (95% CI) |
Mean (SD) | Δ Estimate (95% CI) |
Mean (SD) | Δ Estimate (95% CI) |
P-Value |
| |||||||||
% BP Control (<140/<90 mmHg) | |||||||||
Unadjusted model2 | 60.71 (2.59) | −1.07 (−1.27, −0.87) | 61.79 (2.57) | 0 (Ref) | 62.25 (2.55) | 0.46 (0.21, 0.72) | 61.51 (2.57) | −0.27 (−0.72, 0.18) | <.001 |
Adjusted model | 55.72 (2.40) | −3.88 (−13.42, 5.65) | 59.61 (3.89) | 0 (Ref) | 61.62 (5.43) | 2.02 (−1.41, 5.45) | 58.38 (1.88) | −1.23 (−8.38, 5.93) | 0.010 |
% Improvement in BP | |||||||||
Unadjusted model2 | 29.22 (1.01) | −2.73 (−3.52, −1.93) | 31.95 (0.90) | 0 (Ref) | 29.88 (0.79) | −2.07 (−2.49, −1.65) | 28.93 (0.75) | −3.01 (−3.60, −2.43) | <.001 |
Adjusted model | 24.61 (1.61) | −2.41 (−5.89, 1.07) | 27.02 (1.78) | 0 (Ref) | 24.72 (2.28) | −2.29 (−3.94, −0.65) | 24.34 (1.40) | −2.67 (−5.28, −0.07) | <.001 |
% Medication Intensification | |||||||||
Unadjusted model2 | 10.52 (0.54) | 0.25 (−0.03, 0.53) | 10.27 (0.59) | 0 (Ref) | 9.73 (0.60) | −0.54 (−0.73, −0.35) | 10.23 (0.58) | −0.04 (−0.34, 0.26) | 0.005 |
Adjusted model | 14.29 (1.65) | 1.50 (−1.65, 4.64) | 12.79 (1.59) | 0 (Ref) | 12.05 (1.89) | −0.74 (−1.73, 0.25) | 13.92 (1.60) | 1.12 (−1.45, 3.70) | 0.240 |
Average SBP Reduction after Med Intensification (mmHg) | |||||||||
Unadjusted model2 | 15 (0.22) | −0.73 (−1.01, −0.44) | 16 (0.23) | 0 (Ref) | 15 (0.28) | −0.89 (−1.19, −0.58) | 14 (0.25) | −1.46 (−1.76, −1.16) | <.001 |
Adjusted model | 10 (0.38) | −1.82 (−2.71, −0.94) | 12 (0.37) | 0 (Ref) | 12 (0.57) | −0.17 (−0.73, 0.38) | 10 (0.37) | −2.40 (−3.15, −1.65) | <.001 |
Quarter 2 was used as reference to estimate differences between quarters
Unadjusted model: Quarter Year only
Adjusted model: Unadjusted model+Race/Ethnicity+Sex+Age+Diabetes+HF+CAD+Average Temperature